DBV Technologies (NASDAQ:DBVT) Announces Earnings Results, Misses Estimates By $0.41 EPS

DBV Technologies (NASDAQ:DBVT) issued its quarterly earnings data on Wednesday. The company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.41), FiscalAI reports. DBV Technologies had a negative net margin of 3,506.53% and a negative return on equity of 119.33%. The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $0.58 million.

Here are the key takeaways from DBV Technologies’ conference call:

• DBV submitted its BLA for the VIASKIN Peanut patch in children ages 4–7 and expects to pursue priority review based on the product’s breakthrough therapy designation.
• Fareva Amboise continues remediation following an FDA warning letter related to site-wide quality systems. DBV said progress is on track and that its February 1, 2027 PAI-readiness target provides a buffer, but the FDA reinspection has not yet been scheduled.
• DBV plans to submit a separate BLA for toddlers ages 1–3 in 2027, using a sequential review strategy intended to avoid an FDA bottleneck and leverage learnings from the 4–7 review.
• Cash and cash equivalents totaled $165.7 million, supporting operations into the third quarter of 2027, but operating expenses rose to $164.4 million as the company funded regulatory development and commercial-launch preparations.
• The company is building commercial infrastructure, including plans for a 50–70-person U.S. sales force targeting approximately 4,500 allergists, payer engagement, marketing, and pre-commercial inventory; however, DBV declined to provide first-year sales guidance.

DBV Technologies Trading Up 5.1%

NASDAQ:DBVT opened at $10.65 on Thursday. The stock has a 50 day moving average of $11.71 and a 200-day moving average of $17.00. The firm has a market capitalization of $669.67 million, a PE ratio of -3.03 and a beta of -1.04. DBV Technologies has a 52 week low of $8.63 and a 52 week high of $26.18.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of DBV Technologies in a report on Thursday, September 10th. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a research note on Thursday, October 15th. Citigroup reaffirmed a “market outperform” rating on shares of DBV Technologies in a research report on Thursday. Finally, Wall Street Zen downgraded DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $48.50.

About DBV Technologies

DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.